FLT3 and acute myeloid leukemia: Thus, the aim of this phase 2 trial is to evaluate the efficacy, safety and tolerability of VEN/AZA in comparison to the current SOC in fit patients with newly diagnosed, NPM1-mutated, FLT3-wildtype AML.